Anti-inflammatory and keeping adverse energy downwards capsule for treating asthma, pulmonary emphysema and SARS

Abstract

The capsule for treating asthma, pulmonary emphysema and SARS is developed based on the principle that the Chinese medicine and the Western medicine are complementary and synergistic, and compounded with several kinds of Chinese medicines and Western medicines. It can kill bacteria, resist virus, eliminate circulating disturbance and regulate immunity, and suitable for various people in different disease stages. It has high and stable curative effect. In addition, it has also certain treating effect on hypertension, angiosclerosis, wind-wetness Bi syndrome, etc.

Description

Technical field: [0001] The invention relates to a medicine for treating asthma, emphysema and SARS and a preparation method thereof, in particular to a medicine for treating asthma, emphysema, SARS, which is carefully prepared by combining traditional Chinese medicine and western medicine with the principles of complementarity, promotion and synergy. Medicine for SARS and preparation method thereof. Background technique: [0002] Asthma and emphysema are common diseases, frequently-occurring diseases and difficult diseases. There are 150 million people with asthma and emphysema in the world, and 100,000 people die from this disease every year. The number of patients with asthma and emphysema in my country has exceeded 1,000. In recent years, the incidence rate has been on the rise. "Long course of disease, slow curative effect, difficult to cure, and easy to relapse", inherently "internal disease does not cure asthma", which poses a great danger to the health of the elderly;...

AI Technical Summary

Problems solved by technology

[0002] Asthma and emphysema are common diseases, frequently-occurring diseases and difficult diseases. There are 150 million people with asthma and emphysema in the world, and 100,000 people die from this disease every year. The number of patients with asthma and emphysema in my country has exceeded 1,000. In recent years, the incidence rate has been on the rise. "Long course of disease, slow curative effect, difficult to cure, and easy to relapse", inherently "internal disease does not cure asthma", which poses a great danger to the health of the elderly; especially since the SARS epidemic. Substances have caused unstable factors to the society, taken away many precious lives, caused great losses to people's physical and mental health, and to the country's manpower and property.

[0003] For the treatment of asthma and emphysema, modern medicine focuses on anti-virus, anti-infection, improvement of microcirculation and symptomatic and supportive treatment, which can only relieve symptoms and is difficult to cure. At present, taking antibacterial drugs for a long time will cause side effects, such as flora imbalance , superinfection, etc.; while the drug relaxes the smooth muscle of the trachea, the heart rate increases and the maintenance time is short, with side effects such as headache, dizziness, palpitations, and finger tremors

For the SARS epidemic, at present, it can only focus on prevention and symptomatic treatment. Traditional Chinese medicine combines disease differentiation and syndrome differentiation for the above diseases, and clinical observation and research on the application of multiple prescriptions and compound prescriptions have achieved certain curative effects. However, A reliable and stable preparation with curative effect has not been successfully developed to meet the clinical needs, especially a reliable and stable preparation that combines Chinese and Western medicine to treat such conditions has not been developed. The national patent literature discloses the applicant's patent number ZL 02108357.6's "Anti-inflammatory Shunqi Capsules" formula can be said to fill this gap, but this patented formula needs to be further supplemented, further explained and strengthened